Indeed, a clear dominance of CD8+ T cells in infiltrates has been observed in natalizumab-associated PML-IRIS in patients with multiple sclerosis (MS)7, and in PML-IRIS in HIV-infected patients8. The gene discussed is CD8A; the disease is myeloid sarcoma.